Marieke van Son

185 GENERAL DISCUSSION AND FUTURE PERSPECTIVES REFERENCES 1. Bass EJ, Ahmed HU. Focal therapy in prostate cancer: A review of seven common controversies. Cancer treat- ment reviews. 2016;51:27-34. 2. Kayano PP, Klotz L. Current evidence for focal therapy and partial gland ablation for organ-confined prostate cancer: sys- tematic review of literature published in the last 2 years. Current opinion in urol- ogy. 2021;31(1):49-57. 3. Fallara G, Capogrosso P, Maggio P, Tab- orelli A, Montorsi F, Deho F, et al. Erectile function after focal therapy for localized prostate cancer: a systematic review. International journal of impotence re- search. 2020. 4. Valerio M, Ahmed HU, Emberton M, Lawrentschuk N, Lazzeri M, Montironi R, et al. The role of focal therapy in the management of localised prostate cancer: a systematic review. Eur Urol. 2014;66(4):732-51. 5. Ahdoot M, Lebastchi AH, Turkbey B, Wood B, Pinto PA. Contemporary treatments in prostate cancer focal therapy. Current opinion in oncology. 2019;31(3):200-6. 6. Lebastchi AH, George AK, Polascik TJ, Coleman J, de la Rosette J, Turkbey B, et al. Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An Interna- tional Multidisciplinary Consensus. Eur Urol. 2020;78(3):371-8. 7. AhmedHU, Moore C, Lecornet E, Emberton M. Focal therapy in prostate cancer: de- terminants of success and failure. Jour- nal of endourology. 2010;24(5):819-25. 8. Cookson MS, Aus G, Burnett AL, Can- by-Hagino ED, D’Amico AV, Dmochows- ki RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Pros- tate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. The Journal of urology. 2007;177(2):540-5. 9. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467-79. 10. Roach M, 3rd, Hanks G, Thames H, Jr., Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommenda- tions of the RTOG-ASTRO Phoenix Con- sensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965-74. 11. Stabile A, Orczyk C, Giganti F, Moschini M, Allen C, Punwani S, et al. The Role of Percentage of Prostate-specific Antigen Reduction After Focal Therapy Using High-intensity Focused Ultrasound for Primary Localised Prostate Cancer. Re- sults from a Large Multi-institutional Series. Eur Urol. 2020;78(2):155-60. 12. Barret E, Harvey-Bryan KA, San- chez-Salas R, Rozet F, Galiano M, Cathe- lineau X. How to diagnose and treat focal therapy failure and recurrence? Current opinion in urology. 2014;24(3):241-6. 13. Hamid S, Guillaumier S, Shah T, Arya M, Ahmed HU. Prostate cancer recurrence after Focal Therapy: Treatment op- tions. Archivos espanoles de urologia. 2016;69(6):375-83. 10